AstraZeneca (AZN) and Targacept (TRGT) Announce from Phase 2b Study of AZD3480 Did Not Meet Criteria
Tweet Send to a Friend
AstraZeneca (NYSE: AZN) and Targacept (NASDAQ: TRGT) announced that results from the Phase 2b clinical trial of AZD3480 (TC-1734) conducted ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
